Nationwide Recall Affects Compounded GLP-1 Drugs in Quad-City Area
A nationwide recall is impacting compounded GLP-1 drugs in the Davenport-Rock Island-Moline area because these formulations are not FDA-approved or name-brand.
Davenport Rock Island Moline, IA, October 24, 2026 —
A nationwide recall is affecting compounded GLP-1 drugs in the Davenport-Rock Island-Moline area, according to the information provided. The formulations are described as not FDA-approved or name-brand.
The available information does not identify the products involved, the company or companies responsible, when the recall began, or which agency announced it. It also does not specify the reason for the recall, how many products or units are affected, or whether any injuries or other adverse events have been reported.
No details were provided about where the affected drugs were distributed or how consumers in the area can determine whether a particular product is included. The information also does not state whether pharmacies, prescribers, or regulators have issued additional instructions.
The reported scope is nationwide, with an impact noted in the Davenport-Rock Island-Moline area. Beyond that description, the available account does not clarify the geographic reach or identify specific local providers or locations.
Because key details are missing, the precise products and circumstances covered by the recall cannot be established from the information provided. No further timeline, response from a manufacturer, or next steps were included in the summary.
Story summarized from the original created by Caroline Jaime on www.ourquadcities.com, see more information here.
Media gallery
